Jackson Square Partners LLC raised its position in shares of BIO-TECHNE Corp (NASDAQ:TECH) by 8.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 931,400 shares of the biotechnology company’s stock after purchasing an additional 69,784 shares during the period. Jackson Square Partners LLC’s holdings in BIO-TECHNE were worth $120,662,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the company. Bamco Inc. NY increased its holdings in shares of BIO-TECHNE by 1.4% during the third quarter. Bamco Inc. NY now owns 1,520,228 shares of the biotechnology company’s stock valued at $183,780,000 after acquiring an additional 20,286 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of BIO-TECHNE by 0.5% during the third quarter. Bank of New York Mellon Corp now owns 501,317 shares of the biotechnology company’s stock valued at $60,603,000 after acquiring an additional 2,698 shares in the last quarter. Citadel Advisors LLC increased its holdings in shares of BIO-TECHNE by 28.8% during the fourth quarter. Citadel Advisors LLC now owns 416,736 shares of the biotechnology company’s stock valued at $53,988,000 after acquiring an additional 93,175 shares in the last quarter. First Trust Advisors LP increased its holdings in shares of BIO-TECHNE by 13.7% during the fourth quarter. First Trust Advisors LP now owns 410,991 shares of the biotechnology company’s stock valued at $53,244,000 after acquiring an additional 49,470 shares in the last quarter. Finally, Conestoga Capital Advisors LLC increased its holdings in shares of BIO-TECHNE by 11.5% during the fourth quarter. Conestoga Capital Advisors LLC now owns 274,822 shares of the biotechnology company’s stock valued at $35,603,000 after acquiring an additional 28,240 shares in the last quarter. Hedge funds and other institutional investors own 98.00% of the company’s stock.
In related news, Director Charles A. Dinarello sold 5,000 shares of BIO-TECHNE stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $136.06, for a total value of $680,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.40% of the stock is currently owned by company insiders.
Shares of BIO-TECHNE Corp (TECH) opened at $141.55 on Wednesday. BIO-TECHNE Corp has a twelve month low of $98.22 and a twelve month high of $143.64. The company has a market capitalization of $5,343.42, a PE ratio of 39.17, a P/E/G ratio of 2.61 and a beta of 0.78. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.10 and a quick ratio of 2.49.
BIO-TECHNE (NASDAQ:TECH) last released its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.92 by $0.10. BIO-TECHNE had a return on equity of 14.39% and a net margin of 19.17%. The company had revenue of $154.15 million during the quarter, compared to the consensus estimate of $145.93 million. During the same period last year, the company earned $0.81 EPS. BIO-TECHNE’s revenue for the quarter was up 16.9% on a year-over-year basis. analysts predict that BIO-TECHNE Corp will post 4 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 2nd. Investors of record on Friday, February 16th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Thursday, February 15th. This represents a $1.28 annualized dividend and a yield of 0.90%. BIO-TECHNE’s payout ratio is 41.97%.
TRADEMARK VIOLATION NOTICE: “Jackson Square Partners LLC Purchases 69,784 Shares of BIO-TECHNE Corp (TECH)” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3228531/jackson-square-partners-llc-purchases-69784-shares-of-bio-techne-corp-tech.html.
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BIO-TECHNE Corp (NASDAQ:TECH).
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.